Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | MAP7 | Human | 17alpha-ethynylestradiol | affects expression | ISO | Map7 (Mus musculus) | 6480464 | Ethinyl Estradiol affects the expression of MAP7 mRNA | CTD | PMID:17555576 | MAP7 | Human | 17beta-hydroxy-17-methylestra-4,9,11-trien-3-one | increases expression | EXP | | 6480464 | Metribolone results in increased expression of MAP7 mRNA | CTD | PMID:16751804 | MAP7 | Human | 17beta-hydroxy-5alpha-androstan-3-one | increases expression | EXP | | 6480464 | Dihydrotestosterone results in increased expression of MAP7 mRNA | CTD | PMID:29581250 | MAP7 | Human | 2,2',4,4',5,5'-hexachlorobiphenyl | multiple interactions | ISO | Map7 (Mus musculus) | 6480464 | [2 more ... | CTD | PMID:25510870 | MAP7 | Human | 2,2',5,5'-tetrachlorobiphenyl | multiple interactions | ISO | Map7 (Mus musculus) | 6480464 | [2 more ... | CTD | PMID:25510870 | MAP7 | Human | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Map7 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of MAP7 mRNA | CTD | PMID:21570461 | MAP7 | Human | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | Map7 (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin results in increased expression of MAP7 mRNA | CTD | PMID:33387578 | MAP7 | Human | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | Map7 (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of MAP7 mRNA | CTD | PMID:34747641 | MAP7 | Human | 2,4-dinitrotoluene | affects expression | ISO | Map7 (Rattus norvegicus) | 6480464 | 2 and 4-dinitrotoluene affects the expression of MAP7 mRNA | CTD | PMID:21346803 | MAP7 | Human | 2,6-dinitrotoluene | affects expression | ISO | Map7 (Rattus norvegicus) | 6480464 | 2 and 6-dinitrotoluene affects the expression of MAP7 mRNA | CTD | PMID:21346803 | MAP7 | Human | 3,3',5,5'-tetrabromobisphenol A | increases expression | ISO | Map7 (Rattus norvegicus) | 6480464 | tetrabromobisphenol A results in increased expression of MAP7 mRNA | CTD | PMID:27914987 | MAP7 | Human | 3,4-methylenedioxymethamphetamine | increases expression | ISO | Map7 (Mus musculus) | 6480464 | N-Methyl-3 and 4-methylenedioxyamphetamine results in increased expression of MAP7 mRNA | CTD | PMID:20188158 | MAP7 | Human | 4-hydroxyphenyl retinamide | increases expression | ISO | Map7 (Mus musculus) | 6480464 | Fenretinide results in increased expression of MAP7 mRNA | CTD | PMID:28973697 | MAP7 | Human | 4-hydroxyphenyl retinamide | decreases expression | ISO | Map7 (Mus musculus) | 6480464 | Fenretinide results in decreased expression of MAP7 mRNA | CTD | PMID:28973697 | MAP7 | Human | 5-aza-2'-deoxycytidine | affects expression | EXP | | 6480464 | Decitabine affects the expression of MAP7 mRNA | CTD | PMID:23300844 | MAP7 | Human | 6-propyl-2-thiouracil | decreases expression | ISO | Map7 (Rattus norvegicus) | 6480464 | Propylthiouracil results in decreased expression of MAP7 mRNA | CTD | PMID:24780913 | MAP7 | Human | acrolein | multiple interactions | EXP | | 6480464 | [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of MAP7 mRNA and [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of MAP7 mRNA | CTD | PMID:32699268 | MAP7 | Human | aflatoxin B1 | affects expression | EXP | | 6480464 | Aflatoxin B1 affects the expression of MAP7 protein | CTD | PMID:20106945 | MAP7 | Human | aflatoxin B1 | decreases methylation | EXP | | 6480464 | Aflatoxin B1 results in decreased methylation of MAP7 gene | CTD | PMID:27153756 | MAP7 | Human | aflatoxin B1 | decreases expression | EXP | | 6480464 | Aflatoxin B1 results in decreased expression of MAP7 mRNA | CTD | PMID:22100608 | MAP7 | Human | all-trans-retinoic acid | increases expression | EXP | | 6480464 | Tretinoin results in increased expression of MAP7 mRNA | CTD | PMID:21934132 and PMID:23724009 | MAP7 | Human | alpha-pinene | multiple interactions | EXP | | 6480464 | [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of MAP7 mRNA and [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of MAP7 mRNA | CTD | PMID:32699268 | MAP7 | Human | amitrole | decreases expression | ISO | Map7 (Rattus norvegicus) | 6480464 | Amitrole results in decreased expression of MAP7 mRNA | CTD | PMID:38685447 | MAP7 | Human | aristolochic acid A | decreases expression | EXP | | 6480464 | aristolochic acid I results in decreased expression of MAP7 mRNA | CTD | PMID:33212167 | MAP7 | Human | arsenous acid | increases expression | EXP | | 6480464 | Arsenic Trioxide results in increased expression of MAP7 mRNA | CTD | PMID:15761015 | MAP7 | Human | benzo[a]pyrene | increases expression | EXP | | 6480464 | Benzo(a)pyrene results in increased expression of MAP7 mRNA | CTD | PMID:17879257 | MAP7 | Human | benzo[a]pyrene | decreases expression | EXP | | 6480464 | Benzo(a)pyrene results in decreased expression of MAP7 mRNA | CTD | PMID:32234424 | MAP7 | Human | benzo[a]pyrene | decreases methylation | EXP | | 6480464 | Benzo(a)pyrene results in decreased methylation of MAP7 promoter | CTD | PMID:27901495 | MAP7 | Human | bisphenol A | decreases expression | ISO | Map7 (Mus musculus) | 6480464 | bisphenol A results in decreased expression of MAP7 mRNA | CTD | PMID:26063408 | MAP7 | Human | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of MAP7 protein | CTD | PMID:37567409 | MAP7 | Human | bisphenol A | decreases expression | ISO | Map7 (Rattus norvegicus) | 6480464 | bisphenol A results in decreased expression of MAP7 mRNA | CTD | PMID:30816183 more ... | MAP7 | Human | bisphenol A | affects expression | ISO | Map7 (Rattus norvegicus) | 6480464 | bisphenol A affects the expression of MAP7 mRNA | CTD | PMID:25181051 | MAP7 | Human | butanal | decreases expression | EXP | | 6480464 | butyraldehyde results in decreased expression of MAP7 mRNA | CTD | PMID:26079696 | MAP7 | Human | cadmium dichloride | affects methylation | ISO | Map7 (Rattus norvegicus) | 6480464 | Cadmium Chloride affects the methylation of MAP7 promoter | CTD | PMID:22457795 | MAP7 | Human | cadmium dichloride | increases expression | EXP | | 6480464 | Cadmium Chloride results in increased expression of MAP7 mRNA | CTD | PMID:38382870 | MAP7 | Human | calcitriol | increases expression | EXP | | 6480464 | Calcitriol results in increased expression of MAP7 mRNA | CTD | PMID:26485663 | MAP7 | Human | carbamazepine | affects expression | EXP | | 6480464 | Carbamazepine affects the expression of MAP7 mRNA | CTD | PMID:25979313 | MAP7 | Human | carbon nanotube | decreases expression | ISO | Map7 (Mus musculus) | 6480464 | Nanotubes and Carbon analog results in decreased expression of MAP7 mRNA | CTD | PMID:25554681 | MAP7 | Human | carbon nanotube | increases expression | ISO | Map7 (Mus musculus) | 6480464 | Nanotubes and Carbon results in increased expression of MAP7 mRNA | CTD | PMID:25620056 | MAP7 | Human | CGP 52608 | multiple interactions | EXP | | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to MAP7 gene] | CTD | PMID:28238834 | MAP7 | Human | chlorpyrifos | decreases expression | ISO | Map7 (Mus musculus) | 6480464 | Chlorpyrifos results in decreased expression of MAP7 mRNA | CTD | PMID:37019170 | MAP7 | Human | ciguatoxin CTX1B | affects expression | ISO | Map7 (Mus musculus) | 6480464 | Ciguatoxins affects the expression of MAP7 mRNA | CTD | PMID:18353800 | MAP7 | Human | cisplatin | affects expression | EXP | | 6480464 | Cisplatin affects the expression of MAP7 mRNA | CTD | PMID:23300844 | MAP7 | Human | cisplatin | decreases expression | EXP | | 6480464 | Cisplatin results in decreased expression of MAP7 mRNA | CTD | PMID:27392435 | MAP7 | Human | cisplatin | multiple interactions | EXP | | 6480464 | [Cisplatin co-treated with jinfukang] results in decreased expression of MAP7 mRNA | CTD | PMID:27392435 | MAP7 | Human | cobalt dichloride | increases expression | EXP | | 6480464 | cobaltous chloride results in increased expression of MAP7 mRNA | CTD | PMID:19376846 | MAP7 | Human | cobalt dichloride | decreases expression | ISO | Map7 (Rattus norvegicus) | 6480464 | cobaltous chloride results in decreased expression of MAP7 mRNA | CTD | PMID:24386269 | MAP7 | Human | colforsin daropate hydrochloride | increases expression | EXP | | 6480464 | Colforsin results in increased expression of MAP7 mRNA | CTD | PMID:16751804 | MAP7 | Human | diarsenic trioxide | increases expression | EXP | | 6480464 | Arsenic Trioxide results in increased expression of MAP7 mRNA | CTD | PMID:15761015 | MAP7 | Human | dibutyl phthalate | decreases expression | ISO | Map7 (Mus musculus) | 6480464 | Dibutyl Phthalate results in decreased expression of MAP7 mRNA | CTD | PMID:17361019 and PMID:21266533 | MAP7 | Human | dorsomorphin | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | MAP7 | Human | epoxiconazole | decreases expression | ISO | Map7 (Mus musculus) | 6480464 | epoxiconazole results in decreased expression of MAP7 mRNA | CTD | PMID:35436446 | MAP7 | Human | ethanol | multiple interactions | ISO | Map7 (Mus musculus) | 6480464 | Ethanol affects the expression of and affects the splicing of MAP7 mRNA | CTD | PMID:30319688 | MAP7 | Human | etoposide | affects response to substance | EXP | | 6480464 | MAP7 protein affects the susceptibility to Etoposide | CTD | PMID:16217747 | MAP7 | Human | fenvalerate | increases expression | ISO | Map7 (Rattus norvegicus) | 6480464 | fenvalerate results in increased expression of MAP7 mRNA | CTD | PMID:30307764 | MAP7 | Human | flutamide | increases expression | ISO | Map7 (Rattus norvegicus) | 6480464 | Flutamide results in increased expression of MAP7 mRNA | CTD | PMID:24136188 | MAP7 | Human | FR900359 | decreases phosphorylation | EXP | | 6480464 | FR900359 results in decreased phosphorylation of MAP7 protein | CTD | PMID:37730182 | MAP7 | Human | gentamycin | increases expression | ISO | Map7 (Rattus norvegicus) | 6480464 | Gentamicins results in increased expression of MAP7 mRNA | CTD | PMID:33387578 | MAP7 | Human | inulin | multiple interactions | ISO | Map7 (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Inulin] results in decreased expression of MAP7 mRNA | CTD | PMID:36331819 | MAP7 | Human | isoprenaline | increases expression | ISO | Map7 (Mus musculus) | 6480464 | Isoproterenol results in increased expression of MAP7 mRNA | CTD | PMID:20003209 | MAP7 | Human | ivermectin | decreases expression | EXP | | 6480464 | Ivermectin results in decreased expression of MAP7 protein | CTD | PMID:32959892 | MAP7 | Human | lead(0) | affects expression | EXP | | 6480464 | Lead affects the expression of MAP7 mRNA | CTD | PMID:28903495 | MAP7 | Human | manganese(II) chloride | increases expression | ISO | Map7 (Rattus norvegicus) | 6480464 | manganese chloride results in increased expression of MAP7 mRNA | CTD | PMID:28801915 | MAP7 | Human | medroxyprogesterone acetate | decreases expression | EXP | | 6480464 | Medroxyprogesterone Acetate results in decreased expression of MAP7 mRNA | CTD | PMID:20843944 | MAP7 | Human | mercury dibromide | decreases expression | EXP | | 6480464 | mercuric bromide results in decreased expression of MAP7 mRNA | CTD | PMID:26272509 | MAP7 | Human | mercury dibromide | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7 mRNA | CTD | PMID:27188386 | MAP7 | Human | methapyrilene | decreases expression | ISO | Map7 (Rattus norvegicus) | 6480464 | Methapyrilene results in decreased expression of MAP7 mRNA | CTD | PMID:30467583 | MAP7 | Human | methotrexate | affects response to substance | EXP | | 6480464 | MAP7 protein affects the susceptibility to Methotrexate | CTD | PMID:16217747 | MAP7 | Human | methylmercury chloride | decreases expression | EXP | | 6480464 | methylmercuric chloride results in decreased expression of MAP7 mRNA | CTD | PMID:23179753 and PMID:27188386 | MAP7 | Human | mitomycin C | affects response to substance | EXP | | 6480464 | MAP7 protein affects the susceptibility to Mitomycin | CTD | PMID:16217747 | MAP7 | Human | ozone | multiple interactions | EXP | | 6480464 | [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of MAP7 mRNA more ... | CTD | PMID:32699268 | MAP7 | Human | p-chloromercuribenzoic acid | decreases expression | EXP | | 6480464 | p-Chloromercuribenzoic Acid results in decreased expression of MAP7 mRNA | CTD | PMID:26272509 | MAP7 | Human | p-chloromercuribenzoic acid | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7 mRNA | CTD | PMID:27188386 | MAP7 | Human | paracetamol | decreases expression | EXP | | 6480464 | Acetaminophen results in decreased expression of MAP7 mRNA | CTD | PMID:22230336 | MAP7 | Human | paracetamol | decreases expression | ISO | Map7 (Rattus norvegicus) | 6480464 | Acetaminophen results in decreased expression of MAP7 mRNA | CTD | PMID:33387578 | MAP7 | Human | PCB138 | multiple interactions | ISO | Map7 (Mus musculus) | 6480464 | [2 more ... | CTD | PMID:25510870 | MAP7 | Human | perfluorooctane-1-sulfonic acid | multiple interactions | ISO | Map7 (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Inulin] results in decreased expression of MAP7 mRNA and [perfluorooctane sulfonic acid co-treated with Pectins] results in decreased expression of MAP7 mRNA | CTD | PMID:36331819 | MAP7 | Human | phenylmercury acetate | decreases expression | EXP | | 6480464 | Phenylmercuric Acetate results in decreased expression of MAP7 mRNA | CTD | PMID:26272509 | MAP7 | Human | phenylmercury acetate | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7 mRNA | CTD | PMID:27188386 | MAP7 | Human | pirinixic acid | increases expression | ISO | Map7 (Mus musculus) | 6480464 | pirinixic acid results in increased expression of MAP7 mRNA | CTD | PMID:18301758 and PMID:23811191 | MAP7 | Human | potassium dichromate | decreases expression | EXP | | 6480464 | Potassium Dichromate results in decreased expression of MAP7 protein | CTD | PMID:23718831 | MAP7 | Human | potassium dichromate | affects expression | ISO | Map7 (Mus musculus) | 6480464 | Potassium Dichromate affects the expression of MAP7 mRNA | CTD | PMID:23608068 | MAP7 | Human | progesterone | increases expression | EXP | | 6480464 | Progesterone results in increased expression of MAP7 mRNA | CTD | PMID:18070364 | MAP7 | Human | SB 431542 | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | MAP7 | Human | senecionine | decreases expression | ISO | Map7 (Mus musculus) | 6480464 | senecionine results in decreased expression of MAP7 protein | CTD | PMID:35357534 | MAP7 | Human | sevoflurane | affects expression | ISO | Map7 (Rattus norvegicus) | 6480464 | sevoflurane affects the expression of MAP7 mRNA | CTD | PMID:15967596 | MAP7 | Human | sodium arsenate | increases expression | ISO | Map7 (Mus musculus) | 6480464 | sodium arsenate results in increased expression of MAP7 mRNA | CTD | PMID:30953684 | MAP7 | Human | sodium arsenite | increases expression | EXP | | 6480464 | sodium arsenite results in increased expression of MAP7 mRNA | CTD | PMID:38568856 | MAP7 | Human | tamoxifen | affects expression | ISO | Map7 (Mus musculus) | 6480464 | Tamoxifen affects the expression of MAP7 mRNA | CTD | PMID:17555576 | MAP7 | Human | tetrachloromethane | increases expression | ISO | Map7 (Rattus norvegicus) | 6480464 | Carbon Tetrachloride results in increased expression of MAP7 mRNA | CTD | PMID:31150632 | MAP7 | Human | thioacetamide | decreases expression | ISO | Map7 (Rattus norvegicus) | 6480464 | Thioacetamide results in decreased expression of MAP7 mRNA | CTD | PMID:34492290 | MAP7 | Human | titanium dioxide | increases methylation | ISO | Map7 (Mus musculus) | 6480464 | titanium dioxide results in increased methylation of MAP7 promoter | CTD | PMID:35295148 | MAP7 | Human | titanium dioxide | decreases methylation | ISO | Map7 (Mus musculus) | 6480464 | titanium dioxide results in decreased methylation of MAP7 promoter | CTD | PMID:35295148 | MAP7 | Human | trichostatin A | decreases expression | EXP | | 6480464 | trichostatin A results in decreased expression of MAP7 mRNA | CTD | PMID:24935251 and PMID:26272509 | MAP7 | Human | trichostatin A | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7 mRNA | CTD | PMID:27188386 | MAP7 | Human | triclosan | decreases expression | EXP | | 6480464 | Triclosan results in decreased expression of MAP7 mRNA | CTD | PMID:30510588 | MAP7 | Human | triphenyl phosphate | affects expression | EXP | | 6480464 | triphenyl phosphate affects the expression of MAP7 mRNA | CTD | PMID:37042841 | MAP7 | Human | tungsten | decreases expression | ISO | Map7 (Mus musculus) | 6480464 | Tungsten results in decreased expression of MAP7 mRNA | CTD | PMID:30912803 | MAP7 | Human | valproic acid | affects expression | EXP | | 6480464 | Valproic Acid affects the expression of MAP7 mRNA | CTD | PMID:25979313 | MAP7 | Human | valproic acid | increases expression | EXP | | 6480464 | Valproic Acid results in increased expression of MAP7 mRNA | CTD | PMID:23179753 more ... | MAP7 | Human | valproic acid | decreases expression | EXP | | 6480464 | Valproic Acid results in decreased expression of MAP7 mRNA | CTD | PMID:24935251 | MAP7 | Human | vancomycin | increases expression | ISO | Map7 (Mus musculus) | 6480464 | Vancomycin results in increased expression of MAP7 mRNA | CTD | PMID:18930951 | |